Analyst firms · Citigroup · GSK
Citigroup GSK price target and rating history
GSK plc (GSK) · Health Care
Citigroup rates GSK plc (GSK) Neutral, as of its latest action on Jul 24, 2026. It has published 4 rating actions on GSK since July 2022, including 1 upgrade and 0 downgrades.
- Current rating
- Neutral
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on GSK
- 4
Every Citigroup rating on GSK
- Jul 24, 2026
- Jan 27, 2026
- Feb 13, 2024
- Jul 21, 2022
How other firms rate GSK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Hold | $55.90 | Oct 29, 2026 |
| Wolfe Research | Outperform | $70 | Oct 9, 2026 |
| Berenberg | Buy | Sep 15, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Citigroup | Neutral | Jul 24, 2026 | |
| HSBC | Hold | Jul 6, 2026 | |
| Barclays | Underweight | Jan 6, 2026 | |
| BofA Securities | Neutral | Nov 25, 2025 |
Questions about Citigroup and GSK
- What is Citigroup's rating on GSK?
- Citigroup rates GSK Neutral, a neutral rating, as of Jul 24, 2026.
- When did Citigroup last change its view on GSK?
- On Jul 24, 2026, Citigroup starts coverage at Neutral.
More GSK rating histories
All Citigroup ratingsGSK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.